Science | Nature | Cell | View More
Natural Products
Ramelteon
Ramelteon
ChemFaces products have been cited in many studies from excellent and top scientific journals
Product Name Ramelteon
Price:
CAS No.: 166597-26-9
Catalog No.: CFN90021
Molecular Formula: C13H21NO2
Molecular Weight: 259.34 g/mol
Purity: >=98%
Type of Compound: Alkaloids
Physical Desc.: White powder
Source:
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Download: COA    MSDS    SDF
Similar structural: Comparison (Web)  (SDF)
Guestbook:
Contact Us
Order & Inquiry & Tech Support

Tel: (0086)-27-84237683
Tech: service@chemfaces.com
Order: manager@chemfaces.com
Address: 176, CheCheng Eest Rd., WETDZ, Wuhan, Hubei 430056, PRC
How to Order
Orders via your E-mail:

1. Product number / Name / CAS No.
2. Delivery address
3. Ordering/billing address
4. Contact information
Order: manager@chemfaces.com
Delivery time
Delivery & Payment method

1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

2. We accept: Wire transfer & Credit card & Paypal
Citing Use of our Products
* Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
Size /Price /Stock 10 mM * 1 mL in DMSO / Inquiry
Other Packaging *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap
Our products had been exported to the following research institutions and universities, And still growing.
  • Almansora University (Egypt)
  • University of Queensland (Australia)
  • University of Stirling (United Kingdom)
  • Shanghai University of TCM (China)
  • University of Limpopo (South Africa)
  • Universidade Federal de Santa C... (Brazil)
  • University of Parma (Italy)
  • Yale University (USA)
  • University of Brasilia (Brazil)
  • Universidade da Beira Interior (Germany)
  • Universit?t Basel (Switzerland)
  • More...
Package
Featured Products
Rebaudioside C

Catalog No: CFN90258
CAS No: 63550-99-2
Price: $100/20mg
Platycodin D

Catalog No: CFN98134
CAS No: 58479-68-8
Price: $70/20mg
Sophoraflavanone G

Catalog No: CFN92005
CAS No: 97938-30-2
Price: $138/20mg
Ginsenoside Compound K

Catalog No: CFN99756
CAS No: 39262-14-1
Price: $30/20mg
Hydroxygenkwanin

Catalog No: CFN98021
CAS No: 20243-59-8
Price: $118/20mg
Tussilagone

Catalog No: CFN90629
CAS No: 104012-37-5
Price: $148/20mg
Alpha-caryophyllene

Catalog No: CFN93582
CAS No: 6753-98-6
Price: $40/20mg
Aerugidiol

Catalog No: CFN92621
CAS No: 116425-35-5
Price: $318/5mg
Linoleic acid

Catalog No: CFN93168
CAS No: 60-33-3
Price: $30/20mg
Zederone

Catalog No: CFN92616
CAS No: 7727-79-9
Price: $278/20mg
Related Screening Libraries
Size /Price /Stock 10 mM * 100 uL in DMSO / Inquiry / In-stock
10 mM * 1 mL in DMSO / Inquiry / In-stock
Related Libraries
Biological Activity
Description: Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved for insomnia treatment, it could be a potential therapeutic drug, in adjunctive treatment of learning and memory deficits seen in patients with schizophrenia, it is effective for the prevention of delirium, ramelteon administered nightly to elderly patients admitted for acute care may provide protection against delirium. Ramelteon significantly improves symptoms in patients with gastroesophageal reflux disease and significantly improves patients' sleep experience.
In vivo:
Arch Gen Psychiatry. 2006 Oct;63(10):1149-57.
Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.[Pubmed: 17015817 ]
Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved for insomnia treatment. Most approved insomnia medications have potential for abuse and cause motor and cognitive impairment. To evaluate the potential for abuse, subjective effects, and motor and cognitive-impairing effects of Ramelteon compared with triazolam, a classic benzodiazepine sedative-hypnotic drug.
METHODS AND RESULTS:
In this double-blind crossover study, each participant received oral doses of Ramelteon (16, 80, or 160 mg), triazolam (0.25, 0.5, or 0.75 mg), and placebo during approximately 18 days. All participants received each treatment on different days. Most outcome measures were assessed at 0.5 hours before drug administration and repeatedly up to 24 hours after drug administration.SETTING: Residential research facility.PARTICIPANTS: Fourteen adults with histories of sedative abuse. Subject-rated measures included items relevant to potential for abuse (eg, drug liking, street value, and pharmacological classification), as well as assessments of a broad range of stimulant and sedative subjective effects. Observer-rated measures included assessments of sedation and impairment. Motor and cognitive performance measures included psychomotor and memory tasks and a standing balance task. Compared with placebo, Ramelteon (16, 80, and 160 mg) showed no significant effect on any of the subjective effect measures, including those related to potential for abuse. In the pharmacological classification, 79% (11/14) of subjects identified the highest dose of Ramelteon as placebo. Similarly, compared with placebo, Ramelteon had no effect at any dose on any observer-rated or motor and cognitive performance measure. In contrast, triazolam showed dose-related effects on a wide range of subject-rated, observer-rated, and motor and cognitive performance measures, consistent with its profile as a sedative drug with abuse liability.
CONCLUSIONS:
Ramelteon demonstrated no significant effects indicative of potential for abuse or motor and cognitive impairment at up to 20 times the recommended therapeutic dose and may represent a useful alternative to existing insomnia medications.
J Clin Gastroenterol. 2015 Apr 9.
The Effect of Ramelteon on Heartburn Symptoms of Patients With Gastroesophageal Reflux Disease and Chronic Insomnia: A Pilot Study.[Pubmed: 25887111]
There is a bidirectional relationship between gastroesophageal reflux disease (GERD) and sleep. It has been demonstrated that antireflux treatment can improve sleep quality in GERD patients with nighttime reflux.
METHODS AND RESULTS:
Patients with heartburn and/or regurgitation ≥3 times/week and insomnia for ≥3 months were included. Patients were assessed at baseline with the demographic, GERD symptom assessment scale, Epworth sleepiness scale, Berlin sleep apnea, Pittsburgh sleep quality index, and the Insomnia severity index questionnaires. Subjects underwent an upper endoscopy followed by pH testing. Subsequently, subjects were randomized, in a double-blind, placebo-controlled trial, to receive either Ramelteon 8 mg or placebo before bedtime for 4 weeks. During the last week of treatment, subjects completed a daily GERD symptom and sleep diary and underwent actigraphy. Sixteen patients completed the study, 8 in each arm (mean age and M/F were 48.5 vs. 57.8 y, and 8/0 vs. 6/2, respectively). Patients who received Ramelteon demonstrated a statistically significant decrease in symptom score as compared with those who received placebo for daytime heartburn (-42% vs. -29%), nighttime heartburn (-42% vs. 78%), 24-hour heartburn (-42% vs. -3%), and 24-hour acid regurgitation (-26% vs. 19%) (all P<0.05). Insomnia severity index score was significantly reduced in patients receiving Ramelteon as compared with placebo (-46% vs. -5%, P<0.05). Ramelteon group also demonstrated a significant improvement in sleep efficiency and sleep latency, as compared with placebo, P<0.05). No significant adverse events were observed with Ramelteon.
CONCLUSIONS:
Ramelteon significantly improved symptoms in patients with GERD. In addition, Ramelteon significantly improved patients' sleep experience. Further studies are needed in the future (NCT01128582).
Clin Psychopharmacol Neurosci. 2014 Dec;12(3):215-7.
Effects of Add-on Ramelteon on Cognitive Impairment in Patients with Schizophrenia: An Open-label Pilot Trial.[Pubmed: 25598825]
This open-label study examined the effects of Ramelteon on cognitive functions in 10 outpatients with schizophrenia.
METHODS AND RESULTS:
Ramelteon (8 mg/day) was administered to 10 patients with schizophrenia for six months. The verbal fluency test, Trail-Making Test, the Wisconsin Card Sorting Test, the Stroop Test, the Digit Span Distraction Test, Iowa Gambling Task, the Rey Auditory Verbal Learning Test were evaluated at baseline and 6 months after treatment with Ramelteon. Ramelteon improved significantly the scores of Rey Auditory Verbal Learning Test. Additionally, Ramelteon exerted improvements in the verbal fluency and Iowa Gambling Task in 4 patients.
CONCLUSIONS:
Ramelteon could be a potential therapeutic drug, in adjunctive treatment of learning and memory deficits seen in patients with schizophrenia.
JAMA Psychiatry. 2014 Apr;71(4):397-403.
Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial.[Pubmed: 24554232]
No highly effective interventions to prevent delirium have been identified. To examine whether Ramelteon, a melatonin agonist, is effective for the prevention of delirium. DESIGN, SETTING, AND PARTICIPANTS: A multicenter, rater-blinded, randomized placebo-controlled trial was performed in intensive care units and regular acute wards of 4 university hospitals and 1 general hospital. Eligible patients were 65 to 89 years old, newly admitted due to serious medical problems, and able to take medicine orally. Patients were excluded from the study if they had an expected stay or life expectancy of less than 48 hours.
METHODS AND RESULTS:
Sixty-seven patients were randomly assigned using the sealed envelope method to receive Ramelteon (8 mg/d; 33 patients) or placebo (34 patients) every night for 7 days. Incidence of delirium, as defined by the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition). Ramelteon was associated with a lower risk of delirium (3% vs 32%; P = .003), with a relative risk of 0.09 (95% CI, 0.01-0.69). Even after risk factors were controlled for, Ramelteon was still associated with a lower incidence of delirium (P = .01; odds ratio, 0.07 [95% CI, 0.008-0.54]). The Kaplan-Meier estimates of time to development of delirium were 6.94 (95% CI, 6.82-7.06) days for Ramelteon and 5.74 (5.05-6.42) days for placebo. Comparison by log-rank test showed that the frequency of delirium was significantly lower in patients taking Ramelteon than in those taking placebo (χ(2) = 9.83; P = .002).
CONCLUSIONS:
Ramelteon administered nightly to elderly patients admitted for acute care may provide protection against delirium. This finding supports a possible pathogenic role of melatonin neurotransmission in delirium.
Ramelteon Description
Source:
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
ChemFaces New Products and Compounds
3',5-Dihydroxy-4',6,7-trimethoxyfl...

Catalog No: CFN95316
CAS No: 90850-99-0
Price: $318/5mg
Cannabisin M

Catalog No: CFN95436
CAS No: 1831134-13-4
Price: $318/5mg
Dactylorhin A

Catalog No: CFN95032
CAS No: 256459-34-4
Price: $238/20mg
Peiioside B

Catalog No: CFN95336
CAS No: 1610618-91-1
Price: $318/5mg
Glaucoside A

Catalog No: CFN95299
CAS No: 81474-91-1
Price: $318/5mg
Euphorbia factor L25

Catalog No: CFN95339
CAS No: 303174-98-3
Price: $368/5mg
Ganoderic acid GS-1

Catalog No: CFN95571
CAS No: 1206781-64-7
Price: $413/5mg
Neoorthosiphol A

Catalog No: CFN95447
CAS No: 243448-72-8
Price: $318/10mg
Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

Cell. 2018 Jan 11;172(1-2):249-261.e12.
doi: 10.1016/j.cell.2017.12.019.
IF=36.216(2019)

PMID: 29328914

Cell Metab. 2020 Mar 3;31(3):534-548.e5.
doi: 10.1016/j.cmet.2020.01.002.
IF=22.415(2019)

PMID: 32004475

Mol Cell. 2017 Nov 16;68(4):673-685.e6.
doi: 10.1016/j.molcel.2017.10.022.
IF=14.548(2019)

PMID: 29149595

ACS Nano. 2018 Apr 24;12(4): 3385-3396.
doi: 10.1021/acsnano.7b08969.
IF=13.903(2019)

PMID: 29553709

Nature Plants. 2016 Dec 22;3: 16206.
doi: 10.1038/nplants.2016.205.
IF=13.297(2019)

PMID: 28005066

Sci Adv. 2018 Oct 24;4(10): eaat6994.
doi: 10.1126/sciadv.aat6994.
IF=12.804(2019)

PMID: 30417089
Calculate Dilution Ratios(Only for Reference)
1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.8559 mL 19.2797 mL 38.5594 mL 77.1188 mL 96.3986 mL
5 mM 0.7712 mL 3.8559 mL 7.7119 mL 15.4238 mL 19.2797 mL
10 mM 0.3856 mL 1.928 mL 3.8559 mL 7.7119 mL 9.6399 mL
50 mM 0.0771 mL 0.3856 mL 0.7712 mL 1.5424 mL 1.928 mL
100 mM 0.0386 mL 0.1928 mL 0.3856 mL 0.7712 mL 0.964 mL
* Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
Rebaudioside C

Catalog No: CFN90258
CAS No: 63550-99-2
Price: $100/20mg
Platycodin D

Catalog No: CFN98134
CAS No: 58479-68-8
Price: $70/20mg
Sophoraflavanone G

Catalog No: CFN92005
CAS No: 97938-30-2
Price: $138/20mg
Ginsenoside Compound K

Catalog No: CFN99756
CAS No: 39262-14-1
Price: $30/20mg
Hydroxygenkwanin

Catalog No: CFN98021
CAS No: 20243-59-8
Price: $118/20mg
Tussilagone

Catalog No: CFN90629
CAS No: 104012-37-5
Price: $148/20mg
Alpha-caryophyllene

Catalog No: CFN93582
CAS No: 6753-98-6
Price: $40/20mg
Aerugidiol

Catalog No: CFN92621
CAS No: 116425-35-5
Price: $318/5mg
Linoleic acid

Catalog No: CFN93168
CAS No: 60-33-3
Price: $30/20mg
Zederone

Catalog No: CFN92616
CAS No: 7727-79-9
Price: $278/20mg
Tags: buy Ramelteon | Ramelteon supplier | purchase Ramelteon | Ramelteon cost | Ramelteon manufacturer | order Ramelteon | Ramelteon distributor